Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 23, 2023 at 01:36 am IST
Share
Tyra Biosciences, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 12.9 million compared to USD 9.93 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.24 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to USD 0.24 a year ago.
For the full year, the company reported net loss was USD 55.33 million compared to USD 26.29 million a year ago. Basic loss per share from continuing operations was USD 1.32 compared to USD 1.91 a year ago. Diluted loss per share from continuing operations was USD 1.32 compared to USD 1.91 a year ago.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.